Innovent Biologics and Eli Lilly Enter Strategic Collaboration for the Development and Commercialization of OXM3 in China

Suzhou, China, Aug. 22, 2019 /PRNewswire/ -- Innovent Biologics (HKEX stock code: 01801), a biopharmaceutical company dedicated to the research and development, manufacturing, and commercialization of innovative medicines for the treatment of major diseases such as cancer and autoimmune disorders, announced today that it has entered into a strategic collaboration with Eli Lilly and Company to jointly advance aGastric Acid-Regulating Innovative Compound (OXM3)Development and Commercialization in China.OXM3 is a potential candidate in mid-stage clinical developmentBest-in-classGlucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. The specific terms of the agreement have not been disclosed.

Dr. Yu Dechao, Chairman and President of Innovent Bio, stated, “Innovent Bio is committed to developing high-quality biologics that are affordable to the general public. This collaboration marks a significant milestone for Innovent Bio, through this clinical-stage potentialBest-in-classThe collaboration on this drug will further strengthen our product pipeline and expand our therapeutic areas into diabetes, which is considered the fastest-growing chronic disease worldwide. China is currently the country with the largest diabetic population globally, with approximately 114 million patients. We are very pleased to have reached a collaboration agreement with Eli Lilly and Company on this clinical-stage drug. We look forward to innovative medicinesOXM3 development to meet the clinical needs of a vast patient population in China.”

About OXM3

OXM3 It is a natural peptide analog derived from the post-transcriptional processing of the proglucagon gene in the intestine. Similar to natural peptides,OXM3 Dual agonism of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).OXM3 is a long-acting molecule administered via once-weekly injection.In early-stage clinical trials,OXM3 Oxyntomodulin molecules have demonstrated efficacy in controlling blood glucose levels and reducing body weight in subjects, highlighting their potential therapeutic value in the treatment of diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

About Innovent Bio

“Rooted in Trust, Realized through Action.” It is the vision and goal of Innovent Bio to develop high-quality biologics that are affordable to the general public. Established in 2011, Innovent Bio is dedicated to the development, manufacturing, and commercialization of innovative medicines for the treatment of major diseases such as cancer. On October 31, 2018, Innovent Biologics was listed on the Main Board of The Stock Exchange of Hong Kong Limited, with stock code: 01801.

Currently, the company has established a high-quality technical platform covering the entire lifecycle of innovative biologic drug development, including platforms for R&D, pharmaceutical development and industrialization, clinical research, and marketing, thereby building a comprehensive pipeline that includes21A pipeline of investigational new drug candidates covering oncology, Metabolic DiseasesWaitMultipleIn the disease area, 16 products have entered clinical trials, of which 4 are in Phase III clinical studies. Marketing applications for three monoclonal antibody products have been accepted by the National Medical Products Administration (NMPA), and all have been granted priority review. One product (Sintilimab Injection, brand name: Tyvyt)^®) received approval from the National Medical Products Administration (NMPA) for market launch, with the first approved indication being relapsed/refractory classical Hodgkin lymphoma.

Innovent Bio has assembled a world-class team of experts in the development and industrialization of high-end biologics, including numerous overseas-returning specialists, and has established strategic collaborations with international pharmaceutical companies such as Eli Lilly and Company, Adimab, Incyte, and Hanmi Pharmaceutical. Innovent Bio is committed to working together with all stakeholders to elevate the development of China’s biopharmaceutical industry, thereby improving medication accessibility for the public and fulfilling people’s aspirations for better health and well-being. For more details, please visit the company website:www.innoventbio.com。